Agios Pharmaceuticals Stock Forecast, Price & News

-0.27 (-0.57 %)
(As of 09/22/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume265,515 shs
Average Volume709,918 shs
Market Capitalization$2.76 billion
P/E Ratio2.06
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AGIO News and Ratings via Email

Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Agios Pharmaceuticals logo

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.83 out of 5 stars

Medical Sector

732nd out of 1,352 stocks

Pharmaceutical Preparations Industry

354th out of 665 stocks

Analyst Opinion: 3.2Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Agios Pharmaceuticals (NASDAQ:AGIO) Frequently Asked Questions

Is Agios Pharmaceuticals a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Agios Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AGIO, but not buy additional shares or sell existing shares.
View analyst ratings for Agios Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Agios Pharmaceuticals?

Wall Street analysts have given Agios Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Agios Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Agios Pharmaceuticals?

Agios Pharmaceuticals saw a increase in short interest in the month of August. As of August 13th, there was short interest totaling 5,570,000 shares, an increase of 15.8% from the July 29th total of 4,810,000 shares. Based on an average daily trading volume, of 757,800 shares, the short-interest ratio is presently 7.4 days. Currently, 9.5% of the shares of the company are sold short.
View Agios Pharmaceuticals' Short Interest

When is Agios Pharmaceuticals' next earnings date?

Agios Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Agios Pharmaceuticals

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) posted its quarterly earnings results on Wednesday, July, 28th. The biopharmaceutical company reported ($1.44) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.39) by $0.05. Agios Pharmaceuticals had a negative net margin of 161.11% and a negative trailing twelve-month return on equity of 30.24%.
View Agios Pharmaceuticals' earnings history

How has Agios Pharmaceuticals' stock been impacted by COVID-19?

Agios Pharmaceuticals' stock was trading at $40.87 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AGIO stock has increased by 14.4% and is now trading at $46.74.
View which stocks have been most impacted by COVID-19

What price target have analysts set for AGIO?

11 brokerages have issued 1 year price objectives for Agios Pharmaceuticals' shares. Their forecasts range from $39.00 to $93.00. On average, they expect Agios Pharmaceuticals' stock price to reach $65.00 in the next year. This suggests a possible upside of 39.1% from the stock's current price.
View analysts' price targets for Agios Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Agios Pharmaceuticals' key executives?

Agios Pharmaceuticals' management team includes the following people:
  • Jacqualyn A. Fouse, Chief Executive Officer & Director
  • Jonathan Prim Biller, CFO, Head-Legal & Corporate Affairs
  • Clive Patience, Executive Vice President-Technical Operations
  • Bruce Car, Chief Scientific Officer
  • Darrin Miles, Chief Commercial Officer (LinkedIn Profile)

What is Jackie Fouse's approval rating as Agios Pharmaceuticals' CEO?

11 employees have rated Agios Pharmaceuticals CEO Jackie Fouse on Jackie Fouse has an approval rating of 100% among Agios Pharmaceuticals' employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Agios Pharmaceuticals' key competitors?

What other stocks do shareholders of Agios Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), (CELG), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX).

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

Who are Agios Pharmaceuticals' major shareholders?

Agios Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (13.71%), BlackRock Inc. (10.13%), Vanguard Group Inc. (9.48%), Bellevue Group AG (7.38%), Price T Rowe Associates Inc. MD (5.06%) and State Street Corp (3.34%). Company insiders that own Agios Pharmaceuticals stock include Carman Alenson, Christopher Bowden, Corp /De/ Celgene, Darrin Miles, David P Schenkein and Jacqualyn A Fouse.
View institutional ownership trends for Agios Pharmaceuticals

Which major investors are selling Agios Pharmaceuticals stock?

AGIO stock was sold by a variety of institutional investors in the last quarter, including Woodline Partners LP, Bellevue Group AG, Man Group plc, Vanguard Group Inc., Eagle Health Investments LP, ArrowMark Colorado Holdings LLC, Morgan Stanley, and Morgan Stanley. Company insiders that have sold Agios Pharmaceuticals company stock in the last year include Carman Alenson, Christopher Bowden, and Darrin Miles.
View insider buying and selling activity for Agios Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Agios Pharmaceuticals stock?

AGIO stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Jefferies Group LLC, Northern Trust Corp, Geode Capital Management LLC, State Street Corp, FMR LLC, Nuveen Asset Management LLC, and Charles Schwab Investment Management Inc.. Company insiders that have bought Agios Pharmaceuticals stock in the last two years include Corp /De/ Celgene, David P Schenkein, and Jacqualyn A Fouse.
View insider buying and selling activity for Agios Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Agios Pharmaceuticals' stock price today?

One share of AGIO stock can currently be purchased for approximately $46.74.

How much money does Agios Pharmaceuticals make?

Agios Pharmaceuticals has a market capitalization of $2.76 billion and generates $203.20 million in revenue each year. The biopharmaceutical company earns $-327,370,000.00 in net income (profit) each year or ($4.74) on an earnings per share basis.

How many employees does Agios Pharmaceuticals have?

Agios Pharmaceuticals employs 562 workers across the globe.

What is Agios Pharmaceuticals' official website?

The official website for Agios Pharmaceuticals is

Where are Agios Pharmaceuticals' headquarters?

Agios Pharmaceuticals is headquartered at 88 SIDNEY STREET, CAMBRIDGE MA, 02139.

How can I contact Agios Pharmaceuticals?

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at (617) 649-8600 or via email at [email protected].

This page was last updated on 9/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.